4.3 Patient Profile Requirements & Retrospective DUR
Key Takeaways
- OBRA '90 mandates that pharmacists make a reasonable effort to collect, maintain, and update individual patient profile records for all ambulatory patients.
- Mandatory patient profile data includes demographic information, disease states, known allergies/drug reactions, a complete medication history (including OTCs/herbals), and pharmacist comments.
- Patient profile records and prescription logs must be retained for a minimum of 2 years under federal baseline standards (with many states requiring up to 5 or 10 years).
- Retrospective Drug Utilization Review (RetroDUR) evaluates historical claims data post-dispensing across patient populations to detect fraud, waste, abuse, and inappropriate prescribing patterns.
- State DUR Boards, comprising physicians and pharmacists, review RetroDUR data to establish clinical guidelines and execute prescriber/pharmacist educational interventions.
4.3 Patient Profile Requirements & Retrospective DUR
The third fundamental pillar of the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) encompasses the statutory mandates for patient profile maintenance and Retrospective Drug Utilization Review (RetroDUR). Together, these requirements create a comprehensive longitudinal record of patient care and establish a macro-level quality assurance mechanism across state healthcare systems.
Patient Profile Requirements Under OBRA '90
OBRA '90 mandates that a pharmacy must make a reasonable effort to collect, record, and maintain detailed patient profile records for all ambulatory patients receiving prescription therapy. The patient profile serves as the clinical foundation for all Prospective Drug Utilization Reviews (ProDUR) and counseling evaluations.
Mandatory Data Elements of a Patient Profile
Under OBRA '90 regulations (42 CFR § 456.705) and state pharmacy board rules, the pharmacist or pharmacy staff must attempt to collect and document the following core categories of information:
1. Demographic & Contact Data
- Full legal name of the patient
- Primary residential address and telephone number
- Date of birth (or age) and gender
2. Individual Clinical & Medication History
- Chronic Disease States: Significant medical conditions, chronic illnesses, or physical impairment records (e.g., diabetes, hypertension, end-stage renal disease).
- Known Allergies & Drug Reactions: Documented drug allergies, specific immunological reaction types (e.g., anaphylaxis, rash, angioedema), and history of severe adverse drug reactions.
- Comprehensive Medication List: A complete listing of all prescription medications, over-the-counter (OTC) drugs, herbal remedies, and dietary supplements routinely used by the patient, along with relevant medical devices.
3. Pharmacist Comments & Clinical Observations
- Pharmacist clinical notes regarding drug therapy management.
- Documentation of prior DUR warnings and their clinical resolutions.
- Patient preferences, special communication needs, or documented counseling refusals.
Record Retention Requirements
A critical subject tested on the MPJE is the statutory timeline for preserving pharmacy records, including patient profiles, prescription order logs, and DUR documentation.
- Federal Baseline Standard: Under federal OBRA '90 regulations and the federal Controlled Substances Act (CSA), prescription records and patient profiles must be retained for a minimum of two (2) years from the date of the last entry or dispensing transaction.
- State Law Variations: Many state boards of pharmacy enforce longer retention periods—such as 5, 6, 7, or even 10 years—for patient profiles and prescription records. For the MPJE, candidates must remember that where federal and state laws conflict, the pharmacist must follow the more stringent standard.
Retrospective Drug Utilization Review (RetroDUR)
While Prospective DUR occurs at the point of sale prior to dispensing, Retrospective Drug Utilization Review (RetroDUR) is conducted after medications have been dispensed and consumed by patients.
Mechanics and Data Sources of RetroDUR
RetroDUR relies on big data analytics and electronic claims processing databases. It is primarily executed by:
- State Medicaid Agencies
- Health Maintenance Organizations (HMOs) and Managed Care Organizations (MCOs)
- Pharmacy Benefit Managers (PBMs)
Computers scan millions of paid prescription claims, medical diagnostic codes (ICD-10), and hospital discharge summaries across defined patient populations over rolling periods (e.g., monthly, quarterly, or annually).
Objectives of Retrospective DUR
Unlike Prospective DUR, which protects individual patients in real-time, RetroDUR operates at a population health and systems level. The primary objectives of RetroDUR include:
- Identifying Systemic Prescribing & Dispensing Patterns: Detecting widespread off-guideline prescribing, inappropriate polypharmacy in elderly populations, or chronic under-dosing of essential disease-modifying drugs.
- Detecting Fraud, Waste, and Abuse: Identifying "pill mill" prescribers, fraudulent billing practices, excessive early refills across multiple pharmacies, or patient doctor-shopping schemes.
- Evaluating Therapeutic Duplication Across Multiple Providers: Discovering instances where patients receive duplicate therapies prescribed by different specialists who fail to coordinate care.
- Assessing Clinical Outcomes & Cost Efficacy: Measuring whether state Medicaid drug therapy guidelines correlate with reduced emergency room visits and hospital readmissions.
The Role of the Drug Utilization Review (DUR) Board
OBRA '90 mandated that every state establishing a Medicaid DUR program must appoint an official Drug Utilization Review (DUR) Board.
Composition of the DUR Board
By federal law, the state DUR Board must comprise an equal or balanced representation of healthcare professionals, specifically including:
- Licensed practicing physicians
- Licensed practicing pharmacists
Core Functions & Educational Interventions
The DUR Board reviews the analytical data generated by RetroDUR screening algorithms and formulates policy recommendations. Crucially, the DUR Board does not act primarily as a punitive body; rather, its mandate is educational.
Key DUR Board interventions include:
- Academic Detailing & Provider Education: Sending clinical educational letters to prescribers or pharmacists whose prescribing or dispensing patterns deviate significantly from established clinical practice guidelines.
- Formulary & Prior Authorization Criteria: Establishing evidence-based preferred drug lists (PDLs) and prior authorization criteria for state Medicaid programs.
- Continuing Education Programs: Developing mandatory continuing education modules for pharmacists and prescribers targeting identified areas of medication misuse or safety concerns.
Summary Table: Mandatory vs. Optional Patient Profile Elements
| Profile Category | OBRA '90 Mandatory Elements | Optional / Best Practice Elements |
|---|---|---|
| Demographics | Full name, address, phone #, DOB/age, gender | Emergency contact, primary language spoken |
| Clinical History | Chronic disease states, documented allergies, drug reactions | Height, weight, serum creatinine / CrCl |
| Medication List | All current prescriptions, OTCs, herbals, devices | Preferred pharmacy location, mail preference |
| Pharmacy Notes | Pharmacist clinical comments, DUR resolutions, refusals | Patient insurance copay tier preferences |
Summary Table: Prospective DUR vs. Retrospective DUR Comparison
| Operational Aspect | Prospective DUR (ProDUR) | Retrospective DUR (RetroDUR) |
|---|---|---|
| Primary Execution Time | Prior to dispensing (Point of Sale) | Months/quarters post-dispensing |
| Data Level Analyzed | Single prescription & individual profile | Millions of aggregated electronic claims |
| Primary Executor | Dispensing Community Pharmacist | State DUR Board, Medicaid Agency, PBM |
| Primary Goal | Prevent immediate individual harm | Improve population outcomes, reduce fraud |
| Target Interventions | Contact prescriber, cancel fill, counsel patient | Academic detailing letters, policy edits, CE |
Under OBRA '90 baseline federal standards, what mandatory data elements must a pharmacist make a reasonable effort to collect and record in a patient profile?
What is the minimum record retention period mandated by federal baseline standards for patient profiles and prescription documentation under OBRA '90 and the Controlled Substances Act?
Which of the following best describes the primary objective and methodology of Retrospective Drug Utilization Review (RetroDUR)?
By federal OBRA '90 mandate, what is the required composition and primary operational role of a state Drug Utilization Review (DUR) Board?